Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 2, 2014, Pages 194-203

  Tsimberidou, Apostolia M ^a   Adamopoulos, Alexandra M ^a   Ye, Yang ^a   Piha Paul, Sarina ^a   Janku, Filip ^a   Fu, Siqing ^a   Hong, David ^a   Falchook, Gerald S ^a   Naing, Aung ^a   Wheler, Jennifer ^a   Fortier, Adoneca ^a   Kurzrock, Razelle ^a   Hess, Kenneth R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BENDAMUSTINE; BEVACIZUMAB;

ADENOID CYSTIC CARCINOMA; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANGINA PECTORIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEMALE; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; JAW PAIN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; RASH; SIDE EFFECT; SKIN BLEEDING; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NITROGEN MUSTARD COMPOUNDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895809305     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0020     Document Type: Article

References (17)

1. Balfour JA, Goa KL. Bendamustine. Drugs 2001;61:631-638; discussion 639-640.
2. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492-1501.
3. Bottke D, Bathe K, Wiegel T, et al. Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol 2007;183:128-132. (Pubitemid 46364895)
4. Koster W, Heider A, Niederle N, et al. Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J Thorac Oncol 2:312-316. 2007 (Pubitemid 47181714)
5. Schmittel A, Knodler M, Hortig P, et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007;55:109-113. (Pubitemid 46043579)
6. von Minckwitz G, Chernozemsky I, Sirakova L, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005;16:871-877. (Pubitemid 41215753)
7. Reichmann U, Bokemeyer C, Wallwiener D, et al. Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine. Ann Oncol 2007;18:1981-1984. (Pubitemid 350286235)
8. Eichbaum MH, Schuetz F, Khbeis T, et al. Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study. Anticancer Drugs 2007;18:963-968. (Pubitemid 47220716)
9. Kollmannsberger C, Gerl A, Schleucher N, et al. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs 2000;11:535-539.
10. Ruffert K. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil]. Zentralbl Chir 1998;123(Suppl 5):156-158.
11. Hoffken K, Merkle K, Schonfelder M, et al. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 1998;124:627-632. (Pubitemid 28552999)
12. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-1083.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
14. Tsimberidou AM, Fu S, Ng C, et al. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer 2010;116:4086-4094.
15. Schoffski P, Hagedorn T, Grunwald V, et al. Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours. J Cancer Res Clin Oncol 2000;126:41-47. (Pubitemid 30006350)
16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
17. Reck M, Haering B, Koschel G, et al. [Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine - a phase II study]. Pneumologie 1998;52:570-573.